• KP.3 RBD mRNA Vaccine and Broad Omicron Protection

  2026-09-28

  Guan and colleagues developed a nucleoside-modified, lipid nanoparticle-encapsulated mRNA vaccine encoding the Omicron KP.3 receptor-binding domain and evaluated its stability, immunogenicity, and protective activity in mice. The vaccine induced neutralizing responses across several Omicron subvariants and protected susceptible mice from KP.3 challenge, while also highlighting the need to distinguish antigen design from RNA chemistry and formulation effects.

• CCG-1423: Mapping RhoA Signaling Beyond ROCK

  2026-09-28

  CCG-1423 is a RhoA inhibitor research tool that blocks MRTF-A nuclear import rather than directly inhibiting ROCK1. This article explains how to use that distinction to design more interpretable cancer research assays and assess cautious, exploratory links to viral-entry biology.

• Fluorouracil: Evidence for Solid Tumor Research

  2026-09-27

  Fluorouracil (5-Fluorouracil, 5-FU) inhibits thymidylate synthase through its metabolite FdUMP, limiting dTMP production and DNA synthesis. Product benchmarks and a 2024 breast cancer study support research applications while defining clear limits on model-to-clinic interpretation.

• Targeted Amikacin Delivery into Mycobacterial Granulomas

  2026-09-26

  Montes-Worboys and colleagues tested whether dendritic cells could carry fluorescently labeled amikacin into granulomas in mice infected with Mycobacterium avium. The study demonstrated cell-directed delivery at the 24-hour assessment, supporting a preclinical strategy for concentrating antibiotics at infected tissue while leaving questions about therapeutic efficacy, long-term safety, and clinical translation unresolved.

• Merimepodib (VX-497): Assay Design Guide

  2026-09-25

  A scenario-driven guide to interpreting proliferation and viability assays when inhibiting IMPDH with Merimepodib (VX-497). It covers assay controls, formulation, cross-domain evidence, and practical vendor-selection criteria for SKU B1112.

• (S)-(+)-Methoprene: Practical JH Assays

  2026-09-25

  Use this juvenile hormone analog to probe receptor-driven responses separately from changes in endogenous hormone synthesis. A stage-aware workflow connects Met signaling with developmental and reproductive readouts while highlighting solvent controls, dose finding, and key interpretation limits.

• Nuclear mTORC1 Controls CCAAT-Motif Gene Transcription

  2026-09-24

  The study introduces TerminaTOR, a genetically encodable inhibitor that can be directed to distinct cellular compartments, allowing researchers to distinguish localized mTORC1 functions that global inhibitors cannot resolve. Nuclear targeting revealed a role for nuclear mTORC1 in regulating transcription of CCAAT motif-containing genes, while lysosomal targeting disrupted canonical mTORC1 outputs and induced autophagy.

• Rotigotine: Reading Beyond the Behavioral Signal

  2026-09-24

  Rotigotine is a dopamine D2/D3 receptor agonist whose behavioral effects require careful separation from changes in general activity. This article turns preclinical findings into practical guidance for designing and interpreting depression-related and Parkinson’s disease research.

• (S)-(+)-Methoprene for Juvenile Hormone Assays

  2026-09-23

  Use (S)-(+)-Methoprene to probe how juvenile hormone receptor signaling shapes insect development, while keeping receptor activation distinct from the upstream control of hormone biosynthesis. This workflow pairs dose-controlled treatments with miRNA, gene-expression, and developmental readouts to make results easier to interpret and troubleshoot.

• DiI (DiIC18(3)) Plasma Membrane Probe

  2026-09-23

  DiI (DiIC18(3)) is a lipophilic orange fluorescent membrane dye for labeling plasma membranes in live or fixed cells and tissues, supporting neuronal tracing, migration, adhesion, fusion, and lipoprotein workflows. It requires an organic-solvent stock and is not appropriate for aqueous-only staining, organelle-specific labeling, or detergent-intensive protocols that disrupt membrane localization.

• Fluorouracil: From TS Inhibition to CSC Strategy

  2026-09-22

  Fluorouracil is more than a conventional cytotoxic benchmark: its thymidylate synthase mechanism can be integrated with cancer stem-cell biology, exposure design, and orthogonal translational readouts. This article connects 5-Fluorouracil workflows with TAK1–YAP evidence in gastric cancer stem cells while defining the limits of that cross-domain interpretation.

• Fluorouracil: From DNA Stress to Translation

  2026-09-22

  A translational strategy for using Fluorouracil as a mechanistically anchored benchmark while connecting thymidylate synthase inhibition with tumor-cell state, cancer stem-cell biology, and reproducible preclinical decisions.

• Viral RIPK3 Degradation and Neddylation

  2026-09-21

  Liu et al. identify a family of orthopoxvirus proteins that recruit host SCF machinery to drive RIPK3 degradation, thereby suppressing necroptosis while reshaping virus-induced inflammation and pathogenesis. The study provides a mechanistic framework for examining ubiquitin-proteasome control of innate immunity and for designing follow-up experiments that distinguish pathway dependence from direct substrate targeting.

• (S)-(+)-Methoprene in Insect JH Assays

  2026-09-21

  Use (S)-(+)-Methoprene to separate juvenile hormone receptor signaling from endogenous hormone biosynthesis in developmental, reproductive, and endocrine-disruption assays. This workflow connects transcription factor Met activation with miRNA–mRNA regulation, while practical controls help resolve dosing, solvent, stage, and stability problems.

• Cytochalasin B: A Causal Actin Assay Guide

  2026-09-20

  Cytochalasin B is more than an actin inhibitor: it is a reversible perturbation tool for testing how cytoskeletal architecture controls cellular entry. This guide translates Spiroplasma infection findings into better assay design, controls, and interpretation.

8511 records 1/568 page Next 12345 下5页 Last page